TY - JOUR
T1 - Identification of novel STAT5B mutations and characterization of TCRβ signatures in CD4+ T-cell large granular lymphocyte leukemia
AU - Bhattacharya, Dipabarna
AU - Teramo, Antonella
AU - Gasparini, Vanessa Rebecca
AU - Huuhtanen, Jani
AU - Kim, Daehong
AU - Theodoropoulos, Jason
AU - Schiavoni, Gianluca
AU - Barilà, Gregorio
AU - Vicenzetto, Cristina
AU - Calabretto, Giulia
AU - Facco, Monica
AU - Kawakami, Toru
AU - Nakazawa, Hideyuki
AU - Falini, Brunangelo
AU - Tiacci, Enrico
AU - Ishida, Fumihiro
AU - Semenzato, Gianpietro
AU - Kelkka, Tiina
AU - Zambello, Renato
AU - Mustjoki, Satu
N1 - | openaire: EC/H2020/647355/EU//M-Imm
PY - 2022/2/24
Y1 - 2022/2/24
N2 - CD4+ T-cell large granular lymphocyte leukemia (T-LGLL) is a rare subtype of T-LGLL with unknown etiology. In this study, we molecularly characterized a cohort of patients (n = 35) by studying their T-cell receptor (TCR) repertoire and the presence of somatic STAT5B mutations. In addition to the previously described gain-of-function mutations (N642H, Y665F, Q706L, S715F), we discovered six novel STAT5B mutations (Q220H, E433K, T628S, P658R, P702A, and V712E). Multiple STAT5B mutations were present in 22% (5/23) of STAT5B mutated CD4+ T-LGLL cases, either coexisting in one clone or in distinct clones. Patients with STAT5B mutations had increased lymphocyte and LGL counts when compared to STAT5B wild-type patients. TCRβ sequencing showed that, in addition to large LGL expansions, non-leukemic T cell repertoires were more clonal in CD4+ T-LGLL compared to healthy. Interestingly, 25% (15/59) of CD4+ T-LGLL clonotypes were found, albeit in much lower frequencies, in the non-leukemic CD4+ T cell repertoires of the CD4+ T-LGLL patients. Additionally, we further confirmed the previously reported clonal dominance of TRBV6-expressing clones in CD4+ T-LGLL. In conclusion, CD4+ T-LGLL patients have a typical TCR and mutation profile suggestive of aberrant antigen response underlying the disease.
AB - CD4+ T-cell large granular lymphocyte leukemia (T-LGLL) is a rare subtype of T-LGLL with unknown etiology. In this study, we molecularly characterized a cohort of patients (n = 35) by studying their T-cell receptor (TCR) repertoire and the presence of somatic STAT5B mutations. In addition to the previously described gain-of-function mutations (N642H, Y665F, Q706L, S715F), we discovered six novel STAT5B mutations (Q220H, E433K, T628S, P658R, P702A, and V712E). Multiple STAT5B mutations were present in 22% (5/23) of STAT5B mutated CD4+ T-LGLL cases, either coexisting in one clone or in distinct clones. Patients with STAT5B mutations had increased lymphocyte and LGL counts when compared to STAT5B wild-type patients. TCRβ sequencing showed that, in addition to large LGL expansions, non-leukemic T cell repertoires were more clonal in CD4+ T-LGLL compared to healthy. Interestingly, 25% (15/59) of CD4+ T-LGLL clonotypes were found, albeit in much lower frequencies, in the non-leukemic CD4+ T cell repertoires of the CD4+ T-LGLL patients. Additionally, we further confirmed the previously reported clonal dominance of TRBV6-expressing clones in CD4+ T-LGLL. In conclusion, CD4+ T-LGLL patients have a typical TCR and mutation profile suggestive of aberrant antigen response underlying the disease.
UR - http://www.scopus.com/inward/record.url?scp=85125364011&partnerID=8YFLogxK
U2 - 10.1038/s41408-022-00630-8
DO - 10.1038/s41408-022-00630-8
M3 - Article
C2 - 35210405
AN - SCOPUS:85125364011
SN - 2044-5385
VL - 12
SP - 1
EP - 12
JO - Blood Cancer Journal
JF - Blood Cancer Journal
IS - 2
M1 - 31
ER -